Agent-based models are stochastic modelling procedures, whose most notable characteristic is to be rooted on the specification of local rules attached to the simulated objects –hence “agent based”– informing in turn the computed behaviours (i.e., movement, interaction, replication, death, transformation, etc.). Adoption of agent-based modelling (ABM) in biomedicine and life sciences has seen a rapid growth in the last decades, first and foremost, because AΒM is very appropriate to simulate systems about which researchers have accumulated parcelled local knowledge of datasets acquired by a variety of modalities, and that are interested in exploring how to relate to emerging behaviours. Furthermore, ABM is a rule-based approach that is well-suited to integrate multiple spatio-temporal scales (e.g., intracellular processes, microenvironmental remodelling, multicellular population dynamics, cell-to-tissue and tissue-to-cell interactions, angiogenesis, immuno-surveillance, etc.). The purpose of this minisymposium is to act as a forum for investigators to present the state of the art in ABM in biology and life sciences, with a focus on pathophysiology of chronic (e.g., neuro-developmental and neurodegenerative disorders, cancer, diabetes, chronic inflammation) and communicable diseases (viral infections, parasitic disorders, etc.). Together, we aim to foster the exchange of knowledge and ideas across multiple disciplines: mathematics, physics, computer science, engineering, biology, medicine. We welcome contributions addressing challenges related to mathematical and computational modelling using ABM with particular emphasis in: • cross-scale (from organ to tissue, cell, protein and molecular level) ABM simulations; • challenges in numerical techniques –including high-performance computing procedures– for single scale or/and multiscale agent-based models; • benchmarking and calibration of ABM in problems related to systems biology; • simulations that integrate in vitro and/or in vivo laboratory experiments for ABM initialization, parametrization and/or validation; • prognostic ABM in drug delivery, nanomedicine, immunotherapy, and radiation treatment, with special focus on optimisation of trials and in vivo/ex vivo models substitution/ complementarity.